
The study involved 104 patients undergoing IVF revealed that women with thrombophilia, who were treated with daily enoxaparin (LMWH) from embryo transfer until week 36 of gestation had significantly higher ongoing pregnancy and live birth rates. The untreated thrombophilia group showed lower ongoing pregnancy rates and higher early pregnancy loss and abortion rates.
Like
Save
Share